Personalis has expanded and extended its partnership with Tempus AI to include colorectal cancer in their NeXT Personal MRD test.
Multitarget stool DNA testing is a highly sensitive, non-invasive method for colorectal cancer screening, offering a colonoscopy alternative.
A new AI-based test assesses CD3 immune cells in early-stage bowel cancer tumors to predict recurrence risk.
A new study found that 7.4% of patients repeated fecal testing rather than proceeding directly to colonoscopy as guidelines recommend.
Read More
Offering a choice between colonoscopy and a take-home screening kit more than doubled colorectal cancer screening rates.
Read More
Mainz Biomed N.V. announced results from a clinical study to evaluating integrating its portfolio into its colorectal cancer screening tool.
Read More
Mainz Biomed will present the findings of a study that evaluated its multimodal screening test for the detection of colorectal cancer.
Read More
Geneoscopy received U.S. FDA approval for ColoSense, a noninvasive colorectal cancer screening test that uses RNA biomarkers.
Read More
A significant gap exists in ensuring timely follow-up with colonoscopy after a positive stool test, hindering the effectiveness of screening.
Read More
New studies are cautioning against the use of blood tests to replace established colorectal cancer screening tests.
Read More
Researchers say the test has the best performance for the detection of both colorectal cancer and advanced precancerous polyps.
Read More
The blood test is intended for screening colorectal cancer in people who are of average risk and not experiencing symptoms.
Read More
The PreveCol test for cancer is aimed at the early detection of biomarkers in blood associated with colorectal neoplasia.
Read More
Guardant Health announced the FDA is scheduled to review the premarket approval application for the company’s colorectal cancer blood test.
Read More
Researchers found that about 10% of at-home screening tests for colorectal cancer tests could not be processed, mostly due to patient error.
Read More
DiaCarta has received US FDA 510(k) clearance for its over the counter (OTC) at home iColon Fecal Occult Blood Test (FOBT).
Read More
Universal DX announced a strategic collaboration with Quest Diagnostics designed to improve colorectal cancer screening in the United States.
Read More
Universal DX has announced a strategic collaboration with Quest Diagnostics to improve colorectal cancer screening in the United States.
Read More